CGRP as the target of new migraine therapies — successful translation from bench to clinic

@article{Edvinsson2018CGRPAT,
  title={CGRP as the target of new migraine therapies — successful translation from bench to clinic},
  author={Lars Edvinsson and Kristian Agmund Haanes and Karin Warfvinge and Diana N. Krause},
  journal={Nature Reviews Neurology},
  year={2018},
  volume={14},
  pages={338-350}
}
Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 184 REFERENCES

IUPHAR Review 25

D. L. Hay, M. L. Garelja, D. R. Poyner, Walker, C. S. Update on the pharmacology of calcitoninCGRP fa peptides
  • Br. J. Pharmacol. 175, 3–17
  • 2018

A controlled trial of erenumab for episodic migraine

Goadsby, J P.
  • N. Engl. J. Med
  • 2017

A novel alpha calcitonin generelated peptide analogue protects against endorgan damage in experimental hypertension, cardiac hypertrophy, and heart failure

Aubdool, A A.
  • Circulation 136,
  • 2017

Calcitonin gene - related peptide - targeted therapies for migraine and cluster headache : a review

S. G. Amara, V. Jonas, M. G. Rosenfeld, E. S. Ong, R. M. Evans
  • Clin . Neuropharmacol .
  • 2017